These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 19074424)
21. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. Marx PF; Hackeng TM; Dawson PE; Griffin JH; Meijers JC; Bouma BN J Biol Chem; 2000 Apr; 275(17):12410-5. PubMed ID: 10777524 [TBL] [Abstract][Full Text] [Related]
22. Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor. Higuchi T; Nakamura T; Kakutani H; Ishii H Biol Pharm Bull; 2009 Feb; 32(2):179-85. PubMed ID: 19182372 [TBL] [Abstract][Full Text] [Related]
23. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target. Satoh T; Satoh K; Yaoita N; Kikuchi N; Omura J; Kurosawa R; Numano K; Al-Mamun E; Siddique MA; Sunamura S; Nogi M; Suzuki K; Miyata S; Morser J; Shimokawa H Circ Res; 2017 Apr; 120(8):1246-1262. PubMed ID: 28289017 [TBL] [Abstract][Full Text] [Related]
24. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis. Schneider M; Nesheim M J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552 [TBL] [Abstract][Full Text] [Related]
25. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. Bazzi ZA; Lanoue D; El-Youssef M; Romagnuolo R; Tubman J; Cavallo-Medved D; Porter LA; Boffa MB BMC Cancer; 2016 May; 16():328. PubMed ID: 27221823 [TBL] [Abstract][Full Text] [Related]
26. The impact of the endothelial protein C receptor on thrombin generation and clot lysis. Pepler L; Wu C; Dwivedi DJ; Wu C; Kim PY; Liaw PC Thromb Res; 2017 Apr; 152():30-37. PubMed ID: 28219843 [TBL] [Abstract][Full Text] [Related]
27. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. Kokame K; Zheng X; Sadler JE J Biol Chem; 1998 May; 273(20):12135-9. PubMed ID: 9575159 [TBL] [Abstract][Full Text] [Related]
28. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation. Incampo F; Carrieri C; Semeraro N; Colucci M Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406 [TBL] [Abstract][Full Text] [Related]
29. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. Foley JH; Kim P; Nesheim ME J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711 [TBL] [Abstract][Full Text] [Related]
30. Mutations in the substrate binding site of thrombin-activatable fibrinolysis inhibitor (TAFI) alter its substrate specificity. Zhao L; Buckman B; Seto M; Morser J; Nagashima M J Biol Chem; 2003 Aug; 278(34):32359-66. PubMed ID: 12799375 [TBL] [Abstract][Full Text] [Related]
31. [Regulatory mechanism of fibrinolysis system by thrombin activatable fibrinolysis inhibitor (TAFI)]. Urano T Nihon Yakurigaku Zasshi; 2000 Nov; 116(5):298-303. PubMed ID: 11215380 [TBL] [Abstract][Full Text] [Related]
32. Modulation of TAFI function through different pathways--implications for the development of TAFI inhibitors. Gils A; Ceresa E; Macovei AM; Marx PF; Peeters M; Compernolle G; Declerck PJ J Thromb Haemost; 2005 Dec; 3(12):2745-53. PubMed ID: 16359512 [TBL] [Abstract][Full Text] [Related]
35. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Binette TM; Taylor FB; Peer G; Bajzar L Blood; 2007 Nov; 110(9):3168-75. PubMed ID: 17644733 [TBL] [Abstract][Full Text] [Related]
36. Thrombomodulin allosterically modulates the activity of the anticoagulant thrombin. Rezaie AR; Yang L Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12051-6. PubMed ID: 14523228 [TBL] [Abstract][Full Text] [Related]
37. Activation of protein C by the thrombin-thrombomodulin complex: cooperative roles of Arg-35 of thrombin and Arg-67 of protein C. Yang L; Manithody C; Rezaie AR Proc Natl Acad Sci U S A; 2006 Jan; 103(4):879-84. PubMed ID: 16418283 [TBL] [Abstract][Full Text] [Related]
38. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)--a comparative study assessing the biological equivalence of rat, murine and human TAFI. Hillmayer K; Macovei A; Pauwels D; Compernolle G; Declerck PJ; Gils A J Thromb Haemost; 2006 Nov; 4(11):2470-7. PubMed ID: 17002650 [TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a. Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522 [TBL] [Abstract][Full Text] [Related]
40. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. Marx PF; Brondijk TH; Plug T; Romijn RA; Hemrika W; Meijers JC; Huizinga EG Blood; 2008 Oct; 112(7):2803-9. PubMed ID: 18559974 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]